Denosumab versus zoledronic acid in patients previously treated with zoledronic acid
| Autor: | Ilias Bisbinas, Grigorios T. Sakellariou, Zacharias G. Saridakis, Athina Gkiomisi, Stergios A. Polyzos, Athanasios Papatheodorou, A. D. Anastasilakis, D. Digkas, Panayiotis Kokkoris, Polyzois Makras |
|---|---|
| Rok vydání: | 2015 |
| Předmět: |
Genetic Markers
medicine.medical_specialty Endocrinology Diabetes and Metabolism Zoledronic Acid Bone remodeling chemistry.chemical_compound N-terminal telopeptide Bone Density Internal medicine medicine Humans Osteoporosis Postmenopausal Adaptor Proteins Signal Transducing Aged Bone mineral Lumbar Vertebrae Bone Density Conservation Agents Diphosphonates biology business.industry RANK Ligand Imidazoles Middle Aged Procollagen peptidase Denosumab Zoledronic acid Endocrinology chemistry RANKL Bone Morphogenetic Proteins biology.protein Sclerostin Drug Therapy Combination Female business Biomarkers medicine.drug |
| Zdroj: | Osteoporosis International. 26:2521-2527 |
| ISSN: | 1433-2965 0937-941X |
| DOI: | 10.1007/s00198-015-3174-2 |
| Popis: | Denosumab and zoledronic acid are potent antiresorptives. In this study in patients pre-treated with zoledronic acid, denosumab achieved similar increases with zoledronic acid in lumbar spine BMD despite the more prominent reduction of bone turnover markers. Denosumab reversibly reduced endogenous RANKL. We aimed to compare yearly changes in lumbar spine (LS) bone mineral density (BMD), bone turnover markers, free soluble receptor activator of nuclear factor kappaB ligand (sRANKL) and sclerostin levels between denosumab and zoledronic acid. Postmenopausal women with low bone mass previously treated with zoledronic acid for 1 year were assigned to denosumab injection (n = 32) or zoledronic acid infusion (n = 26). Procollagen type 1 N-terminal propeptide (P1NP), C-terminal cross-linking telopeptide of type 1 collagen (CTx), sRANKL, and sclerostin levels were measured in serum samples obtained at baseline and 3, 6, and 12 months after denosumab injection or zoledronic acid infusion. LS BMD was measured at baseline and 12 months. The mean LS increase was 4.5 and 4.4 % with denosumab and zoledronic acid, respectively (p = 0.560). Denosumab caused a larger decrease in CTx at 3 months (p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink